Abstract
Pharmacogenetics investigates heritable genetic polymorphisms that can effect responses to drug therapy. The main application of pharmacogenetics is genotype-guided dosing of medications and genotype-selection of treatment with the highest efficacy and lowest risk of adverse effects.
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity globally. Dyslipidemia is one of the classical risk factors for developing CVD. 3-hydroxy-3-methylglutaryl-coenzyme (HMGCoA) reductase inhibitors called statins are the cornerstones in dyslipidemia treatment. However, there is a broad variation in individual responses to statin treatment. This variation may not only be due to environmental factors such as adherence to treatment, diet and exercise but also due to genetic factors.
Many studies have focused on various genetic polymorphisms of genes that are involved in cholesterol metabolism, trying to define their contribution to a potential genotype-guided treatment against dyslipidemia.
Keywords: Statins, pharmacogenetics, gene polymorphisms, cholesterol.
Current Vascular Pharmacology
Title:Pharmacogenetics and Statin Treatment: Reality or Theory?
Volume: 13 Issue: 5
Author(s): Eleni Bousoula, Vana Kolovou, Despoina Perrea and Genovefa Kolovou
Affiliation:
Keywords: Statins, pharmacogenetics, gene polymorphisms, cholesterol.
Abstract: Pharmacogenetics investigates heritable genetic polymorphisms that can effect responses to drug therapy. The main application of pharmacogenetics is genotype-guided dosing of medications and genotype-selection of treatment with the highest efficacy and lowest risk of adverse effects.
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity globally. Dyslipidemia is one of the classical risk factors for developing CVD. 3-hydroxy-3-methylglutaryl-coenzyme (HMGCoA) reductase inhibitors called statins are the cornerstones in dyslipidemia treatment. However, there is a broad variation in individual responses to statin treatment. This variation may not only be due to environmental factors such as adherence to treatment, diet and exercise but also due to genetic factors.
Many studies have focused on various genetic polymorphisms of genes that are involved in cholesterol metabolism, trying to define their contribution to a potential genotype-guided treatment against dyslipidemia.
Export Options
About this article
Cite this article as:
Bousoula Eleni, Kolovou Vana, Perrea Despoina and Kolovou Genovefa, Pharmacogenetics and Statin Treatment: Reality or Theory?, Current Vascular Pharmacology 2015; 13 (5) . https://dx.doi.org/10.2174/1570161113666150130165651
DOI https://dx.doi.org/10.2174/1570161113666150130165651 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
Current Medicinal Chemistry Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism Statins and Solid Organ Transplantation
Current Pharmaceutical Design Association of Admission Leukocyte Count with Clinical Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator
Current Neurovascular Research Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews Central Hemodynamics for Risk Reduction Strategies: Additive Value Over and Above Brachial Blood Pressure
Current Pharmaceutical Design Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients
Current Pharmaceutical Biotechnology Beta-Blockers in Children with Congenital Heart Disease Before a Corrective Procedure
Reviews on Recent Clinical Trials Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Preoperative Plasma Aldosterone Levels and Postoperative Atrial Fibrillation Occurrence Following Cardiac Surgery: A Review of Literature and Design of the ALDO-POAF Study (ALDOsterone for Prediction of Post-Operative Atrial Fibrillation)
Current Clinical Pharmacology The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews The Diagnosis of Drug-Induced Liver Disease
Current Clinical Pharmacology Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Cyclodextrins as Food Additives and in Food Processing
Current Nutrition & Food Science Non-invasive Atherosclerosis Imaging: Use to Assess Response to Novel or Combination Lipid Therapies
Current Drug Targets - Cardiovascular & Hematological Disorders Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Psychosocial Implications During Adolescence for Infant Heart Transplant Recipients
Current Cardiology Reviews Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets